Company / Current Liabilities
Edwards Lifesciences Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$1.8B
FY2025
5-year range
$1.0B / $1.8B
FY2021-FY2025
Trend
+20.5%
vs FY2024
Sector context
#37 of 160
Health Care
What the data says
Edwards Lifesciences's current liabilities of $1.8B is higher than 77% of companies in the Health Care sector (FY2025). Current Liabilities has increased for 3 consecutive years, from $1.0B in FY2022 to $1.8B in FY2025.
Based on SEC 10-K filings.
$1.8B in FY2025 with a 5-year CAGR of +15.2%. Top quartile in the Health Care sector.
Increased from $1.2B to $1.8B over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +21.1%
- 5-Year CAGR
- +15.2%
- 10-Year CAGR
- -
Sector benchmark
-59.5% below sector average
Key checks
Key Insights
- Edwards Lifesciences's current liabilities has grown for 3 consecutive years.
- 5-year CAGR of +15.2%, indicating consistent growth.
- In FY2025, current liabilities increased 20.5% year-over-year.
- Ranks #37 out of 160 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.8B | +20.5% |
| FY2024 | $1.5B | +25.9% |
| FY2023 | $1.2B | +16.9% |
| FY2022 | $1.0B | -1.0% |
| FY2021 | $1.0B | +15.5% |
| FY2020 | $893.9M | -0.9% |
| FY2019 | $902.4M | +2.9% |
| FY2018 | $876.6M | -38.3% |
| FY2017 | $1.4B | +166.7% |
| FY2016 | $532.5M | +11.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026